Enoximone

This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H12N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7Z4ITI7L7, chemically known as 1,3-dihydro-4-methyl-5-(4-methylthiobenzoyl)-2h-imidazol-2-one but generally known as enoximone, which bears US NIH Compound Identifier 53708. European Medicines Agency schedules Enoximone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06542MIG. The term ENOXIMONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules enoximone in its Anatomical Therapeutic Chemical (ATC) Classification. ENOXIMONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enoximone under HS 29332990 and SITC 51573. As of Q4 2014, ENOXIMONE remains the US FDA Preferred Term for this commodity. Enoximone bears US NLM identifiers UMLS ID C0116190 and NCI Concept Code C87375. SMILES: CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)SC.